Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis

PLoS Pathog. 2008 Feb 29;4(2):e1000028. doi: 10.1371/journal.ppat.1000028.

Abstract

We report that natural killer T (NKT) cells play only a minor physiological role in protection from Leishmania donovani infection in C57BL/6 mice. Furthermore, attempts at therapeutic activation of invariant NKT (iNKT) cells with alpha-galactosylceramide (alpha-GalCer) during L. donovani infection exacerbated, rather than ameliorated, experimental visceral leishmaniasis. The inability of alpha-GalCer to promote anti-parasitic immunity did not result from inefficient antigen presentation caused by infection because alpha-GalCer-loaded bone marrow-derived dendritic cells were also unable to improve disease resolution. The immune-dampening affect of alpha-GalCer correlated with a bias towards increased IL-4 production by iNKT cells following alpha-GalCer stimulation in infected mice compared to naïve controls. However, studies in IL-4-deficient mice, and IL-4 neutralisation in cytokine-sufficient mice revealed that alpha-GalCer-induced IL-4 production during infection had only a minor role in impaired parasite control. Analysis of liver cell composition following alpha-GalCer stimulation during an established L. donovani infection revealed important differences, predominantly a decrease in IFNgamma+ CD8+ T cells, compared with control-treated mice. Our data clearly illustrate the double-edged sword of NKT cell-based therapy, showing that in some circumstances, such as when sub-clinical or chronic infections exist, iNKT cell activation can have adverse outcomes.

MeSH terms

  • Animals
  • Antibodies, Blocking / pharmacology
  • Biomarkers
  • CD8-Positive T-Lymphocytes
  • Disease Models, Animal
  • Female
  • Galactosylceramides / therapeutic use
  • Gene Silencing
  • Host-Parasite Interactions
  • Immunologic Factors / therapeutic use
  • Interferon-gamma
  • Interleukin-4 / deficiency
  • Interleukin-4 / immunology
  • Interleukin-4 / metabolism
  • Killer Cells, Natural / immunology*
  • Leishmania donovani / immunology
  • Leishmania donovani / pathogenicity*
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / immunology*
  • Leishmaniasis, Visceral / pathology
  • Liver / drug effects
  • Liver / metabolism
  • Liver / parasitology
  • Lymphocyte Activation
  • Lymphocyte Subsets / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Knockout
  • RNA, Messenger / metabolism

Substances

  • Antibodies, Blocking
  • Biomarkers
  • Galactosylceramides
  • Immunologic Factors
  • RNA, Messenger
  • alpha-galactosylceramide
  • Interleukin-4
  • Interferon-gamma